ILMN - Illumina, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
+3.25 (+1.57%)
At close: 04:00PM EDT
210.49 -0.07 (-0.03%)
After hours: 06:46PM EDT
Stock chart is not supported by your current browser
Previous close207.31
Bid0.00 x 1300
Ask0.00 x 800
Day's range206.91 - 213.11
52-week range173.45 - 248.87
Avg. volume1,279,891
Market cap33.29B
Beta (5Y monthly)1.18
PE ratio (TTM)N/A
EPS (TTM)-30.08
Earnings date09 Aug 2023 - 14 Aug 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est238.92
  • Reuters

    Illumina appeals FTC order to divest cancer test maker Grail

    WASHINGTON (Reuters) -Illumina on Monday filed an appeal against a Federal Trade Commission (FTC) order, demanding that it divest cancer diagnostic test maker Grail over competition concerns in the U.S. market for cancer tests. San Diego-based Illumina is arguing that the FTC "violated due process by depriving Illumina and Grail of a fair proceeding before an impartial tribunal," according to the filing in the U.S. Fifth Circuit Court of Appeals.

  • Zacks

    Illumina's (ILMN) New AI Tool to Predict Genomics Disease

    Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.

  • Zacks

    Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?

    Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Reuters

    Illumina expands board after fight with Icahn

    On Friday it named Stephen MacMillan, CEO of diagnostics products company Hologic Inc, and Scott Ullem, CFO of heart valve systems maker Edwards Lifesciences Corp, as new directors. Wall Street analysts welcomed the move, with analysts at Evercore ISI writing: "Steve and Scott are well known and respected by Wall Street and should bring a ton of confidence into the (Illumina) story."

  • Zacks

    Why Is Repligen (RGEN) Up 2.7% Since Last Earnings Report?

    Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Zacks

    Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23

    At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.

  • Reuters

    Illumina CEO survived Icahn's challenge by more than 2-to-1 margin

    Illumina Inc CEO Francis deSouza survived a challenge to his board seat from activist investor Carl Icahn last week by securing more than twice the shareholder votes than the number his challenger received, the company said in a filing on Tuesday. It gives deSouza legitimacy to carry on after Icahn mustered enough shareholder support to oust Illumina's board chair John Thompson and install one of his board nominees, Andrew Teno.

  • Simply Wall St.

    12% Of This Illumina Insider's Holdings Were Sold \

    Insiders were net sellers of Illumina, Inc.'s ( NASDAQ:ILMN ) stock during the past year. That is, insiders sold more...

  • Reuters

    Icahn scores partial Illumina win amid pressure to defend investment acumen

    NEW YORK (Reuters) -Carl Icahn secured a seat on Thursday for one of his three nominees to the board of gene sequencing machine maker Illumina Inc, a partial victory for the activist investor who is struggling to burnish his credentials following a shortseller attack on his company. Illumina said Icahn nominee Andrew Teno won enough shareholder votes for election, confirming an earlier Reuters report. Illumina's market value of $30 billion made the fight this year's largest proxy contest to go to a shareholder vote.

  • Bloomberg

    Icahn Wins One Board Seat in Illumina Proxy Fight

    (Bloomberg) -- Illumina Inc. shareholders voted to elect a board member nominated by activist shareholder Carl Icahn, a much-needed partial victory for the billionaire as his investment firm grapples with an attack by short-seller Hindenburg Research. Most Read from BloombergCathie Wood’s ARKK Dumped Nvidia Stock Before $560 Billion SurgeApple Plans to Turn Locked iPhones Into Smart Displays With iOS 17JPMorgan Tells 1,000 First Republic Employees They'll Lose Their JobsFirst Republic’s $35 Mill


    Midday movers: Nvidia, Illumina, American Eagle Outfitters and more -- Stocks are mixed on Thursday as tech gets a boost from Nvidia's strong outlook while Dow stocks are weaker on a lack of resolution in the debt ceiling negotiations. Here are the market movers for May 25.

  • Reuters

    Icahn poised to win at least one seat on Illumina's board - sources

    NEW YORK (Reuters) -Activist investor Carl Icahn is set to win enough Illumina Inc shareholder support to install at least one of his three nominees to the gene sequencing machine maker's board, two people familiar with the matter said on Wednesday.

  • Simply Wall St.

    Does Illumina (NASDAQ:ILMN) Have A Healthy Balance Sheet?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

  • Zacks

    Illumina (ILMN) Progresses in Pathogen Genomic Technologies

    Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.

  • Simply Wall St.

    What Is Illumina, Inc.'s (NASDAQ:ILMN) Share Price Doing?

    Let's talk about the popular Illumina, Inc. ( NASDAQ:ILMN ). The company's shares received a lot of attention from a...

  • Reuters

    Proxy adviser ISS backs one of Icahn's nominees for Illumina board

    ISS backed Icahn's candidate Andrew Teno and said he could be an adequate replacement for Illumina Chairman John Thompson, but did not support any other Icahn nominee. The partial backing by ISS comes just two days after another proxy adviser, Glass Lewis, backed Teno and another Icahn nominee, and said shareholders should vote against the re-election of current CEO Francis deSouza and Chairman Thompson.

  • Simply Wall St.

    Illumina (NASDAQ:ILMN) shareholders are up 6.6% this past week, but still in the red over the last three years

    As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...

  • Reuters

    Glass Lewis backs two of Icahn's nominees for Illumina

    Glass Lewis added shareholders should vote against the re-election of the current chief Francis deSouza and chair John Thompson, saying they had enough reasons to advocate for a new chair. The recommendations come ahead of the company's annual shareholder meeting on May 25, which could bring to an end the two-month long proxy battle between Illumina and billionaire investor Carl Icahn.

  • Simply Wall St.

    Is Illumina, Inc. (NASDAQ:ILMN) Worth US$200 Based On Its Intrinsic Value?

    Key Insights Illumina's estimated fair value is US$164 based on 2 Stage Free Cash Flow to Equity Illumina is estimated...

  • Motley Fool

    Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

    Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the market and still has a lot to prove to its investors as well as the scientific community, Illumina is the top dog that's fighting to maintain its position. Bulls argue that Illumina is the better gene sequencing stock because in some sequencing markets, it's basically the only option in town, particularly in the all-important market for next generation sequencers (NGS).

  • Motley Fool

    Why Illumina Fell 11.6% in April

    The gene-sequencing company reported weaker results while the Federal Trade Commission has ordered it to divest its Grail acquisition.

  • Zacks

    Illumina (ILMN) Q1 Earnings Beat Estimates, Margins Contract

    Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.

  • Zacks

    Illumina (ILMN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

    While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

  • Zacks

    Illumina (ILMN) Beats Q1 Earnings and Revenue Estimates

    Illumina (ILMN) delivered earnings and revenue surprises of 300% and 2.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Zacks

    EXEL or ILMN: Which Is the Better Value Stock Right Now?

    EXEL vs. ILMN: Which Stock Is the Better Value Option?